Niagen Bioscience Inc (NASDAQ: NAGE) is a Healthcare company (Biotechnology) with a market capitalization of $162M. The Maz Rating grades it against the other companies in its sector.
Niagen Bioscience Inc's current Maz Rating and its five factor grades are for members: log in to see them.
At $2.04, Niagen Bioscience Inc trades at 16.0x trailing earnings, 1.3x sales and 1.9x book value, with an EV/EBITDA of 13.6. Over the last twelve months it generated about $123M of revenue and $10M of net income. It runs a gross margin of 63.9%, an operating margin of 2.3% and a net margin of 8.4%. It shows return on equity of 12.6%, return on invested capital of 2.8% and a free cash flow yield of 2.8%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 5.93. Over the past 52 weeks the share price ranged from $1.95 to $7.12, with a beta of 2.09.
Niagen Bioscience Inc does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.